Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis
ConditionCerebral Venous Thrombosis
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorKafrelsheikh University
About this trial
Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral heamoragic complications.
Eligibility criteria
Qualifiers
Patients aged 18 and above
New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT/CT venogram or MRI/MR venogram
Ability to randomize within 14 days of neuroimaging-confirmed diagnosis
The treating clinician is of the opinion that the patient is appropriate for oral anticoagulation as per the standard of care
Disqualifiers
The patient has known antiphospholipid antibody syndrome with a previous history of venous or arterial thrombosis
The patient is anticipated to require invasive procedures (e.g., lumbar puncture, thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation
Patient is unable to swallow due to depressed level of consciousness
Impaired renal function (i.e., CrCl < 30 mL/min using CockroftGault equation)
Trial design
Treatments tested in this trial
- Apixaban 5MG
- Rivaroxaban 20 MG Oral Tablet
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov